Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for atrial fibrillation recurrence and atrial remodeling after catheter ablation
ChiCTR2200063258Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin in Atrial fibrillation (AFib), type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Union Hospital. Primary endpoints: Left atrial end-diastolic volume, Left ventricular end-diastolic volume and 1 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)type 2 diabetes mellitus (T2DM)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR2200063258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063258.